In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Is There A Cure For Old Age?

Longevity Therapeutics Developers Aim To Find Out

Executive Summary

Investment and research into the science of aging – and therapeutics that could slow down or even reverse the aging process – are ramping up. Past clinical failures have given way to new and focused approaches that aim to lengthen “healthspan,” turning the last years of life into the best years of life.     

You may also be interested in...



Do It Yourself: Advantages Of Internal Gene Therapy Manufacturing

The number of gene therapies in development continues to rise, as trial sponsors widen the scope of addressable conditions, beyond ultra-rare diseases. Will manufacturing capacity – and payer budgets – be able to keep up?

Designing Disruptive Business Models For Unmet Medical Need

An undergraduate class in abnormal psychology and a lifelong interest in technology helped to set Michael Hufford on a career path that now includes the co-founding of five companies. As CEO of Harm Reduction Therapeutics, a nonprofit pharmaceutical company, Hufford hopes to make a cheap, OTC version of naloxone widely available to help prevent unnecessary deaths from opioid overdoses.

Using Data To Improve Rare Disease Diagnosis And Treatment

A deeper understanding of rare diseases – how they differ across geographies and ethnicities, or which genes and biomarkers are most useful targets for new treatments – can help to accelerate and de-risk clinical trials. On the commercial front, patient data and insights could mean the difference between a category leader and a failure.

Topics

UsernamePublicRestriction

Register

IV124819

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel